Are single-nucleotide polymorphisms in reductase genes associated with response to daunorubicin-based remission induction?
Despite their showing in vitro effect on metabolic rate of daunorubicin, the nonsynonymous SNPs in the reductase genes on their own are not significant contributors to the observed variability in response to daunorubicin therapy and thus, as singularities, are not useful biomarkers of this outcome.
This proof of concept study finds preliminary support for the potential utility of SSRIs in managing Bipolar II Disorder, with clear improvements in depression and impairment and some suggested benefit for hypomania.